Compositions and methods for treatment of lung function

A method for treating an individual at risk for non-linear lung function decline, comprising

• a) determining, in said individual, a covariate comprising one or more biomarker selected from Immunoglobulin alpha-1 heavy chain constant region;
• kappa 1 immunoglobulin constant;
• Immunoglobulin kappa light chain VLJ region;
• immunoglobulin lambda;
• Immunoglobulin lambda constant 2;
• Immunoglobulin lambda constant 3;
• Tight junction protein 3;
• Alpha-1-acid glycoprotein 2 precursor;
• Signal-induced proliferation-associated 1-like protein 3;
• Plakophilin 4;
• Inter-alpha (globulin) inhibitor H2;
• Absent in melanoma 1 protein;
• Actin filament-associated protein 1 isoform X2;
• Serine/threonine-protein phosphatase PP1-beta catalytic subunit;
• Retinol-binding protein 4;
• Fermitin family homolog 1;
• Actin, cytoplasmic 2;
• Transthyretin;
• Melanoma inhibitory activity protein 3 isoform X2;
• Pleckstrin homology domain-containing family G member 1 isoform X3;
• Pleckstrin homology domain-containing family A member 5 isoforms X1-X9;
• Pleckstrin;
• Zinc finger protein 295;
• Protocadherin Fat 2;
• Cadherin-related family member 2 isoform X1;
• Voltage gated calcium channel alpha 1F subunit;
• Actin filament associated protein;
• Heat shock 70 kDa protein 1-like;
• EF-hand calcium binding protein 2;
• Polyamine modulated factor-1 (PMF1) protein;
• Keratin 16;
• Keratin 18;
• DNA replication ATP-dependent helicase/nuclease DNA2 isoform X4;
• Non-lens beta gamma-crystallin like protein;
• Bromodomain and WD repeat-containing protein 1 isoform X1;
• Collagen type V alpha 3 chain;
• Collagen type IV alpha;
• Dynein heavy chain 12, axonemal isoform X5;
• Serine/arginine repetitive matrix protein 1;
• Ras-related protein Rap-1A;
• AT-hook-containing transcription factor isoform 1;
• Coiled-coil domain-containing protein 18 isoforms X1-X7;
• Coiled-coil domain-containing protein 180;
• Patatin-like phospholipase domain-containing protein 2 isoform X1;
• Alstrom syndrome protein 1 isoform 1;
• aminopeptidase O isoform X9 (C9orf3);
• ankyrin-3 isoform 3;
• ARAP2 protein (ARAP2);
• Bifunctional glutamate/proline-tRNA ligase (EPRS);
• C10ORF6;
• CECR2 protein (CECR2);
• cingulin-like 1 (CGNL1);
• coiled-coil domain-containing protein 93 isoform X3 (CCDC93);
• complement component C2 (C2);
• complement component C6 isoform X7 (C6);
• complement factor H (CFH);
• connector enhancer of kinase suppressor of ras 2 isoform X2 (CNKSR2);
• CTP:phosphocholine cytidylyltransferase;
• DNA annealing helicase and endonuclease ZRANB3 (ZRANB3);
• EPRSN1;
• fibrinogen alpha chain preproprotein, isoform alpha (FGA);
• filamin 2 (FLN2);
• Fras1-related extracellular matrix protein 2 (FREM2);
• FYVE, RhoGEF and PH domain-containing protein 5 isoform X2 (FGD5);
• gelsolin isoform X3 (GSN);
• glutamate receptor-interacting protein 1 isoform X7 (GRIP1);
• hCG1656772;
• histidine-rich glycoprotein isoform X1 (HRG);
• interferon regulatory factor-2 binding protein 2B;
• junction-mediating and -regulatory protein isoform X2 (JMY);
• KIAA0328 protein KIAA0328;
• 1a-related protein 1 isoform X5 LARP1;
• MAX gene-associated protein isoform X11 (MGA);
• paraoxanase-3;
• Platelet glycoprotein Ib alpha chain (GP1BA);
• PMFBP1 protein (PMFBP1);
• PRO2841;
• protein arginine N-methyltransferase 3 isoform X1 (PRMT3);
• Protein SCAF11 (SCAF11);
• ral GTPase-activating protein subunit alpha-1 isoform X12 (RALGAPA1);
• Receptor-type tyrosine-protein phosphatase C (PTPRC);
• RGS3 isoform C2PA-RGS3 (RGS3);
• Rho-GTPase activating protein 10 (ARHGAP10);
• RNA-binding motif protein, Y chromosome, family 1 member B isoform X1 (RBMY1B);
• protein-methionine sulfoxide oxidase MICAL3 isoform X10 (MICAL3);
• Protein sidekick-2 (SDK2);
• sacsin isoform X3 (SACS);
• SAPS domain family, member 2 (SAPS2);
• serum aryldialkylphosphatase precursor;
• spermatogenesis-associated protein 31C1 isoform X1 (SPATA31C1);
• synaptotagmin-like protein 2 isoform X10 (SYTL2);
• translation initiation factor (IF2);
• triadin isoform X17 (TRDN);
• uridine-cytidine kinase-like 1 isoform X7 (UCKL1);
• utrophin isoform X4 (UTRN);
• WD repeat-containing protein 64 isoform X2 (WDR64);
• zinc finger and AT hook domain containing (ZFAT);
• Alstrom syndrome protein 1 isoform 1;
• aminopeptidase O isoform X9 (C9orf3);
• ankyrin-3 isoform 3;
• ARAP2 protein (ARAP2);
• Bifunctional glutamate/proline-tRNA ligase (EPRS);
• C10ORF6;
• CECR2 protein (CECR2);
• cingulin-like 1 (CGNL1);
• coiled-coil domain-containing protein 93 isoform X3 (CCDC93);
• complement component C2 (C2);
• complement component C6 isoform X7 (C6);
• complement factor H (CFH);
• connector enhancer of kinase suppressor of ras 2 isoform X2 (CNKSR2);
• CTP:phosphocholine cytidylyltransferase;
• DNA annealing helicase and endonuclease ZRANB3 (ZRANB3);
• EPRSN1;
• fibrinogen alpha chain preproprotein, isoform alpha (FGA);
• filamin 2 (FLN2);
• Fras1-related extracellular matrix protein 2 (FREM2);
• FYVE, RhoGEF and PH domain-containing protein 5 isoform X2 (FGD5);
• gelsolin isoform X3 (GSN);
• glutamate receptor-interacting protein 1 isoform X7 (GRIP1);
• hCG1656772;
• histidine-rich glycoprotein isoform X1 (HRG);
• interferon regulatory factor-2 binding protein 2B;
• junction-mediating and -regulatory protein isoform X2 (JMY);
• KIAA0328 protein KIAA0328;
• 1a-related protein 1 isoform X5 LARP1;
• MAX gene-associated protein isoform X11 (MGA);
• paraoxanase-3;
• Platelet glycoprotein Ib alpha chain (GP1BA);
• PMFBP1 protein (PMFBP1);
• PRO2841;
• protein arginine N-methyltransferase 3 isoform X1 (PRMT3);
• Protein SCAF11 (SCAF11);
• ral GTPase-activating protein subunit alpha-1 isoform X12 (RALGAPA1);
• Receptor-type tyrosine-protein phosphatase C (PTPRC);
• RGS3 isoform C2PA-RGS3 (RGS3);
• Rho-GTPase activating protein 10 (ARHGAP10);
• RNA-binding motif protein, Y chromosome, family 1 member B isoform X1 (RBMYlB);
• protein-methionine sulfoxide oxidase MICAL3 isoform X10 (MICAL3);
• Protein sidekick-2 (SDK2);
• sacsin isoform X3 (SACS);
• SAPS domain family, member 2 (SAPS2);
• serum aryldialkylphosphatase precursor;
• spermatogenesis-associated protein 31C1 isoform X1 (SPATA31C1);
• synaptotagmin-like protein 2 isoform X10 (SYTL2);
• translation initiation factor (IF2);
• triadin isoform X17 (TRDN);
• uridine-cytidine kinase-like 1 isoform X7 (UCKL1);
• utrophin isoform X4 (UTRN);
• WD repeat-containing protein 64 isoform X2 (WDR64);
• zinc finger and AT hook domain containing (ZFAT);
• b) calculating a risk probability score based on said determining of one or more covariate, said risk probability score being used to characterize the individual as having no predicted lung impairment, mild predicted lung impairment, moderate predicted lung impairment, or severe predicted lung impairment wherein said risk probability score comprises a risk probability of said non-linear lung function decline in one or more parameters selected from a decrease in forced expiratory volume in one second (FEV1), pulmonary exacerbation (PE) frequency, FEV1-indicated exacerbation signal (FIES), ventilation defect percent (VDP), abnormal lung heterogeneity in lung as measured via imaging, lung hyperinflation, and combinations thereof;
• and
• c) treating said individual characterized as having mild predicted lung impairment, moderate predicted lung impairment, or severe predicted lung impairment with anti-inflammatory therapy.